ATE342357T1 - Verwendung von chimären proteinen im transport von ausgewählten substanten in die zelle - Google Patents

Verwendung von chimären proteinen im transport von ausgewählten substanten in die zelle

Info

Publication number
ATE342357T1
ATE342357T1 AT96919035T AT96919035T ATE342357T1 AT E342357 T1 ATE342357 T1 AT E342357T1 AT 96919035 T AT96919035 T AT 96919035T AT 96919035 T AT96919035 T AT 96919035T AT E342357 T1 ATE342357 T1 AT E342357T1
Authority
AT
Austria
Prior art keywords
chimeric proteins
selected substance
transport
dna encoding
chimeric
Prior art date
Application number
AT96919035T
Other languages
English (en)
Inventor
Michael W Heartlein
Jeffrey F Lemontt
Michael F Concino
Original Assignee
Transkaryotic Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transkaryotic Therapies Inc filed Critical Transkaryotic Therapies Inc
Application granted granted Critical
Publication of ATE342357T1 publication Critical patent/ATE342357T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT96919035T 1995-06-06 1996-06-03 Verwendung von chimären proteinen im transport von ausgewählten substanten in die zelle ATE342357T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/470,058 US5817789A (en) 1995-06-06 1995-06-06 Chimeric proteins for use in transport of a selected substance into cells

Publications (1)

Publication Number Publication Date
ATE342357T1 true ATE342357T1 (de) 2006-11-15

Family

ID=23866103

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96919035T ATE342357T1 (de) 1995-06-06 1996-06-03 Verwendung von chimären proteinen im transport von ausgewählten substanten in die zelle

Country Status (14)

Country Link
US (4) US5817789A (de)
EP (1) EP0832225B1 (de)
JP (1) JP4276295B2 (de)
KR (1) KR100509261B1 (de)
CN (1) CN1161465C (de)
AT (1) ATE342357T1 (de)
AU (1) AU723350B2 (de)
CA (1) CA2221711A1 (de)
DE (1) DE69636621T2 (de)
IL (2) IL122381A0 (de)
MY (1) MY137300A (de)
NZ (1) NZ310657A (de)
TW (1) TW517060B (de)
WO (1) WO1996039510A1 (de)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482937B1 (en) * 1997-10-09 2002-11-19 Biotransplant, Inc. Porcine Oct-4 promoter
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
US6887712B1 (en) * 1998-11-09 2005-05-03 Atherogenics, Inc. Methods and compositions to lower plasma cholesterol levels
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
JP2003523948A (ja) * 1999-11-04 2003-08-12 アンドルクス コーポレーション アミロイドβ前駆体障害の治療法
US20020107173A1 (en) * 1999-11-04 2002-08-08 Lawrence Friedhoff Method of treating amyloid beta precursor disorders
AU1647501A (en) 1999-12-10 2001-06-18 Cytos Biotechnology Ag Replicon based activation of endogenous genes
US6316256B1 (en) 2000-01-03 2001-11-13 Tr Associates, L.L.C. Method for protein transfer
US7435585B2 (en) * 2000-01-03 2008-10-14 University Of Pennsylvania Auto-stimulating cells and methods for making and using the same
AU785028C (en) * 2000-02-08 2007-05-03 Bioasis Advanced Technologies Inc. Compositions and methods for screening therapeutic agents
WO2002042462A2 (en) * 2000-11-27 2002-05-30 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
EP1363935B1 (de) * 2001-02-07 2012-11-14 Life Technologies Corporation Ter-stellen und ter-bindende proteine
US6542814B2 (en) * 2001-03-07 2003-04-01 Horizon Navigation, Inc. Methods and apparatus for dynamic point of interest display
IL142118A0 (en) * 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
EP1383492A4 (de) * 2001-03-23 2008-12-24 Napro Biotherapeutics Inc Molekulare konjugate zur verwendung in der krebstherapie
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
EP1974752B1 (de) * 2001-04-30 2012-09-26 BioMarin Pharmaceutical Inc. Subzelluläres Targeting von therapeutischen Proteinen
US7629309B2 (en) * 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
GB0112652D0 (en) * 2001-05-24 2001-07-18 Inst Of Molecul & Cell Biology Internalisation of virus into cells
AU2002322720B2 (en) * 2001-07-25 2008-11-13 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US6867189B2 (en) * 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
BR0212256A (pt) 2001-08-30 2004-08-31 Biorexis Pharmaceutical Corp Proteìnas de fusão de transferrina modificadas
US7176278B2 (en) * 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
US20070031440A1 (en) * 2001-08-30 2007-02-08 Prior Christopher P Modified transferin-antibody fusion proteins
US20030072761A1 (en) * 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
DE60326153D1 (de) * 2002-07-30 2009-03-26 David Gladstone Inst Verfahren zur diagnose von morbus alzheimer
AU2003257109A1 (en) * 2002-08-05 2004-02-23 Invitrogen Corporation Compositions and methods for molecular biology
CA2492324A1 (en) * 2002-08-14 2004-03-11 Blanchette Rockefeller Neurosciences Institute Method for isolating subpopulations of proteins that engage in protein-protein interactions
US20060105387A1 (en) * 2002-08-30 2006-05-18 Prior Christopher P Transferrin fusion proteins libraries
US20060130158A1 (en) * 2002-08-30 2006-06-15 Turner Andrew J Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
SI1551876T1 (sl) 2002-10-16 2011-07-29 Purdue Pharma Lp Protitelesa, ki se vežejo na celično povezan CA 125/0722P, in postopki za njihovo uporabo
AU2004212944B2 (en) * 2003-02-14 2008-08-21 Children's Hospital & Research Center At Oakland Lipophilic drug delivery vehicle and methods of use thereof
US20070060512A1 (en) * 2003-03-04 2007-03-15 Homayoun Sadeghi Dipeptidyl-peptidase protected protein
US7379700B2 (en) * 2003-05-06 2008-05-27 Canon Kabushiki Kaisha Image reading apparatus with rotatable internal and external guides
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
AU2004263681A1 (en) * 2003-08-04 2005-02-17 Laboratoires Serono Sa Novel therapeutic fusion proteins
WO2005021579A2 (en) * 2003-08-28 2005-03-10 Biorexis Pharmaceutical Corporation Epo mimetic peptides and fusion proteins
US20060205037A1 (en) * 2003-08-28 2006-09-14 Homayoun Sadeghi Modified transferrin fusion proteins
CA2553955C (en) * 2004-02-10 2012-08-28 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
CN101146826A (zh) * 2005-01-24 2008-03-19 得克萨斯大学体系董事会 与磷脂酰丝氨酸结合的fc融合构建体及其治疗用途
JP2008546392A (ja) * 2005-06-17 2008-12-25 バイオレクシス ファーマシューティカル コーポレーション 固定されたトランスフェリン融合タンパク質ライブラリー
KR101193722B1 (ko) * 2006-07-24 2013-01-11 바이오렉시스 파마슈티칼 코포레이션 엑센딘 융합 단백질
CA2669347A1 (en) * 2006-11-13 2008-05-29 Zystor Therapeutics, Inc. Methods for treating pompe disease
ES2535358T3 (es) 2006-12-12 2015-05-08 Biorexis Pharmaceutical Corporation Bibliotecas de proteínas de fusión de transferrina
PL2118123T3 (pl) 2007-01-31 2016-06-30 Dana Farber Cancer Inst Inc Stabilizowane peptydy p53 i ich zastosowania
JP5631201B2 (ja) 2007-03-28 2014-11-26 プレジデント アンド フェローズ オブ ハーバード カレッジ ステッチングされたポリペプチド
IL182956A0 (en) * 2007-05-03 2008-01-20 Yeda Res & Dev Glycan modified soluble receptors and binding proteins and their use
EP2191849B1 (de) * 2007-09-26 2018-08-01 National Cerebral and Cardiovascular Center Wirkstoff zur suppression von in vivo auftretenden krankheitserregern
KR20100091191A (ko) * 2007-10-26 2010-08-18 쉐링 코포레이션 항-ｐｃｓｋ9, 및 지질 및 콜레스테롤 질환의 치료 방법
ES2629853T3 (es) * 2008-05-07 2017-08-16 Biomarin Pharmaceutical Inc. Péptidos de dirección lisosómica y usos de los mismos
WO2009158678A1 (en) 2008-06-27 2009-12-30 Children's Hospital & Research Center At Oakland Lipophilic nucleic acid delivery vehicle and methods of use therefor
EP2475376B1 (de) 2009-06-17 2016-03-30 BioMarin Pharmaceutical Inc. Formulierungen für lysosomale enzyme
JP2013505300A (ja) 2009-09-22 2013-02-14 エルロン・セラピューティクス・インコーポレイテッド ペプチド模倣大環状分子
CN102770458A (zh) * 2009-12-02 2012-11-07 阿塞勒隆制药公司 用于增加Fc融合蛋白的血清半寿期的组合物和方法
WO2012021144A1 (en) 2010-08-12 2012-02-16 New York University Oligooxopiperazines and methods of making and using them
KR102104762B1 (ko) 2010-08-13 2020-04-24 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
WO2012075037A1 (en) 2010-11-30 2012-06-07 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor
EP2658567A4 (de) 2010-12-28 2014-09-24 Univ Rochester Verfahren zur modifikation einer insulinsignalübertragung mittels biliverdinreduktase (bvr) und bvr-abgeleiteten peptiden
ES2586411T3 (es) 2011-03-04 2016-10-14 New York University Macrociclos sustitutos de enlace de hidrógeno como moduladores de Ras
EP2718328A4 (de) 2011-06-08 2014-12-24 Acceleron Pharma Inc Zusammensetzungen und verfahren zur erhöhung der halbwertszeit von serum
EP3741384A1 (de) 2011-09-07 2020-11-25 Mount Sinai School Of Medicine Ceramidase und zelldifferenzierung
EP2768518A4 (de) 2011-10-18 2015-05-27 Aileron Therapeutics Inc Peptidomimetische makrozyklen
CN103160565A (zh) * 2011-12-09 2013-06-19 彩虹天健康科技研究(北京)有限责任公司 Unc-51激酶影响细胞运铁蛋白的胞吞作用
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
RU2642299C2 (ru) 2012-02-15 2018-01-24 Эйлерон Терапьютикс, Инк. P53 пептидомиметические макроциклы
CN104334541A (zh) 2012-02-16 2015-02-04 纽约大学 使用低聚氧代哌嗪非肽螺旋模拟物对低氧诱导基因表达的控制
CN109529028A (zh) 2012-06-01 2019-03-29 西奈山伊坎医学院 在感染的治疗和预防中的神经酰胺水平
US9321749B1 (en) 2012-07-25 2016-04-26 Globavir Biosciences, Inc. Heterocyclic compounds and uses thereof
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
WO2014160390A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Therapeutic acid ceramidase compositions and methods of making and using them
GB201322396D0 (en) 2013-12-18 2014-02-05 Univ Nottingham Transduction
CA2946392A1 (en) * 2014-04-25 2015-10-29 James M. Wilson Ldlr variants and their use in compositions for reducing cholesterol levels
EP3197478A4 (de) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetische makrozyklen und verwendungen davon
CN107106642B (zh) 2014-09-24 2021-02-26 艾瑞朗医疗公司 拟肽大环化合物及其制剂
JP2018516844A (ja) 2015-03-20 2018-06-28 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその使用
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP3347372A4 (de) 2015-09-10 2019-09-04 Aileron Therapeutics, Inc. Peptidomimetische makrocyclen als modulatoren von mcl-1
WO2018109666A1 (en) 2016-12-15 2018-06-21 Nestec Sa Compositions and methods that modulate cholesterol in a companion animal
IT201900000651A1 (it) 2019-01-16 2019-04-16 Pastore Lucio Tecnologia di trasferimento genico
CN110218259B (zh) * 2019-06-24 2022-09-16 王跃驹 植物生产胰高血糖素样肽-1短肽与转铁蛋白的融合蛋白制造口服降糖胶囊的应用
CN110256579A (zh) * 2019-06-24 2019-09-20 王跃驹 植物生产人胰岛素与转铁蛋白长效口服降糖胶囊的应用
TW202545976A (zh) * 2024-02-16 2025-12-01 相佑 林 治療性蛋白質靶向細胞核遞送平臺
WO2026052839A1 (en) * 2024-09-06 2026-03-12 Hone Bio Limited Targeting fusion proteins

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668255A (en) * 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5554386A (en) * 1986-07-03 1996-09-10 Advanced Magnetics, Inc. Delivery of therapeutic agents to receptors using polysaccharides
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5292869A (en) * 1989-04-27 1994-03-08 The Board Of Governors Of The University Method for isolating and purifying transferrin and lactoferrin receptor proteins from bacteria and the preparation of vaccines containing the same
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5527527A (en) * 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5154924A (en) * 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5182107A (en) * 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
AU654811B2 (en) * 1990-03-20 1994-11-24 Trustees Of Columbia University In The City Of New York, The Chimeric antibodies with receptor binding ligands in place of their constant region
US6248332B1 (en) * 1990-10-05 2001-06-19 Medarex, Inc. Targeted immunostimulation with bispecific reagents
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
WO1993000917A1 (en) * 1991-07-05 1993-01-21 Seragen, Inc. Epidermal growth factor receptor targeted molecules for treatment of inflammatory arthritis
US5433946A (en) 1991-10-11 1995-07-18 Health Research Inc. Synthesis and utilization of therapeutic agents for the treatment of lysosomal storage diseases
US5571507A (en) * 1992-02-25 1996-11-05 Seragen, Inc. Methods of treating diabetes
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
AU4238893A (en) * 1992-05-07 1993-11-29 Regents Of The University Of California, The Novel diphtheria toxin-based molecules
US5608003A (en) 1995-06-23 1997-03-04 Minnesota Mining And Manufacturing Company Aqueous fluorochemical compositions and abrasion-resistant coatings therefrom

Also Published As

Publication number Publication date
HK1015414A1 (en) 1999-10-15
CN1190438A (zh) 1998-08-12
US6027921A (en) 2000-02-22
MY137300A (en) 2009-01-30
WO1996039510A1 (en) 1996-12-12
IL122381A (en) 2008-07-08
KR19990022535A (ko) 1999-03-25
AU723350B2 (en) 2000-08-24
DE69636621T2 (de) 2007-08-30
US6262026B1 (en) 2001-07-17
DE69636621D1 (de) 2006-11-23
EP0832225A1 (de) 1998-04-01
EP0832225B1 (de) 2006-10-11
JP4276295B2 (ja) 2009-06-10
CA2221711A1 (en) 1996-12-12
IL122381A0 (en) 1998-06-15
AU6148296A (en) 1996-12-24
US5817789A (en) 1998-10-06
US6858578B2 (en) 2005-02-22
CN1161465C (zh) 2004-08-11
NZ310657A (en) 2000-01-28
KR100509261B1 (ko) 2008-11-07
US20010025026A1 (en) 2001-09-27
JPH11509084A (ja) 1999-08-17
TW517060B (en) 2003-01-11

Similar Documents

Publication Publication Date Title
DE69636621D1 (de) Verwendung von chimären proteinen im transport von ausgewählten substanten in die zelle
DE3785102D1 (de) Verfahren zur herstellung von faktor-viii:c-typ-proteinen.
NO308310B1 (no) Hovedsakelig rent KGF protein og dets anvendelse
NO963371L (no) Hematopoietisk protein samt materialer og fremgangsmåter for fremstilling av det
EP0759170A4 (de) Verwendung von grünem fluoreszenzprotein
ATE124725T1 (de) Verbessertes verfahren zur herstellung von faktor viii:c-typ-proteinen.
AU8661498A (en) Mammalian cell membrane proteins; related reagents
DK0789766T3 (da) Kimæriske papillomaviruslignende partikler
MX174477B (es) Inmunoensayo amperometrico homogeneo
ATE135371T1 (de) Mit akuter pankreatitis assoziiertes protein, mittel zur diagnose von akuter pankreatitis
NZ211357A (en) Recombinant dna and antigenic protein coded for
AU9356398A (en) Bioassay for thyroid stimulating antibodies
ATE87101T1 (de) Immuntestverfahren und satz.
DE3650468D1 (de) Methoden zur Verwendung von an humanen Klasse-II-Histokompatibilitätsantigenen mangelnden Zellinien
WO1999027094A3 (en) HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND DNAs ENCODING THESE PROTEINS
ATE288476T1 (de) Herstellung von proteinen
Lewis Mechanism of Action of Interferon-gamma
SE9900134D0 (sv) A method for introducing substances into cells, and use of said method
UA31874A (uk) Спосіб прогнозування помутніння задньої капсули кришталика

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0832225

Country of ref document: EP

EEFA Change of the company name